Apr 28, 2022 / 07:00PM GMT
Mayank Mamtani - B. Riley Securities, Inc. - Analyst
Good afternoon. This is Mayank Mamtani, senior biotech analyst. Thank you for joining us for our next company presentation. I am pleased to have with me Denali's Chief Scientific Officer, Joe Lewcock.
Joe thank you for making the time from the busy schedule to join us today. Really appreciate it. I think we'll pass it on to you. You have a set of slides that you'd like to walk through, and then I can come back at the end with Q&A. Please take it away.
Joe Lewcock - Denali Therapeutics Inc. - Chief Scientific Officer
Yeah, sounds good. Thanks, Mayank, for the introduction and really appreciate you having us. And super excited today to take you -- take everyone through a quick overview of what's going at Denali Therapeutics. So just to start, some very quick disclaimers before we get going, and then let's just dive into the data.
So Denali was founded about seven years ago really with the unique focus on addressing neurodegenerative disease. And when we say neurodegenerative disease, we're
Denali Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers